Becton, Dickinson and Company (NYSE:BDX) Stake Boosted by Kennebec Savings Bank

Kennebec Savings Bank raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 40.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 269 shares of the medical instruments supplier’s stock after acquiring an additional 77 shares during the period. Kennebec Savings Bank’s holdings in Becton, Dickinson and Company were worth $64,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of BDX. Livelsberger Financial Advisory bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $33,000. Tompkins Financial Corp lifted its stake in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Sound Income Strategies LLC grew its position in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Finally, Versant Capital Management Inc increased its holdings in shares of Becton, Dickinson and Company by 54.1% in the fourth quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 73 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Up 0.6 %

Becton, Dickinson and Company stock opened at $248.34 on Friday. The firm’s 50 day moving average price is $229.59 and its two-hundred day moving average price is $233.55. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $250.91. The firm has a market cap of $72.02 billion, a PE ratio of 41.81, a P/E/G ratio of 1.79 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.42 earnings per share. On average, research analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.68%. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

BDX has been the subject of several analyst reports. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler raised their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.00.

Get Our Latest Analysis on Becton, Dickinson and Company

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.